318 related articles for article (PubMed ID: 25824409)
1. Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression.
Wang S; Wang L; Chen M; Wang Y
Chem Biol Interact; 2015 Jun; 235():76-84. PubMed ID: 25824409
[TBL] [Abstract][Full Text] [Related]
2. Gambogic acid-loaded pH-sensitive mixed micelles for overcoming breast cancer resistance.
Wang S; Yang Y; Wang Y; Chen M
Int J Pharm; 2015 Nov; 495(2):840-8. PubMed ID: 26407923
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.
Nestal de Moraes G; Vasconcelos FC; Delbue D; Mognol GP; Sternberg C; Viola JP; Maia RC
Eur J Cell Biol; 2013; 92(8-9):247-56. PubMed ID: 24064045
[TBL] [Abstract][Full Text] [Related]
4. Gambogic acid sensitizes ovarian cancer cells to doxorubicin through ROS-mediated apoptosis.
Wang J; Yuan Z
Cell Biochem Biophys; 2013 Sep; 67(1):199-206. PubMed ID: 23436279
[TBL] [Abstract][Full Text] [Related]
5. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
6. Alopecurone B reverses doxorubicin-resistant human osteosarcoma cell line by inhibiting P-glycoprotein and NF-kappa B signaling.
Xia YZ; Ni K; Guo C; Zhang C; Geng YD; Wang ZD; Yang L; Kong LY
Phytomedicine; 2015 Mar; 22(3):344-51. PubMed ID: 25837271
[TBL] [Abstract][Full Text] [Related]
7. BME, a novel compound of anthraquinone, down regulated P-glycoprotein expression in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells via generation of reactive oxygen species.
Wang J; Liu L; Cen J; Ji B
Chem Biol Interact; 2015 Sep; 239():139-45. PubMed ID: 26169035
[TBL] [Abstract][Full Text] [Related]
8. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K
Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008
[TBL] [Abstract][Full Text] [Related]
9. Targeting Cellular Metabolism Chemosensitizes the Doxorubicin-Resistant Human Breast Adenocarcinoma Cells.
Ma S; Jia R; Li D; Shen B
Biomed Res Int; 2015; 2015():453986. PubMed ID: 26558272
[TBL] [Abstract][Full Text] [Related]
10. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells.
Chakravarty G; Mathur A; Mallade P; Gerlach S; Willis J; Datta A; Srivastav S; Abdel-Mageed AB; Mondal D
Biochimie; 2016 May; 124():53-64. PubMed ID: 26844637
[TBL] [Abstract][Full Text] [Related]
11. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Xu HB; Li L; Liu GQ
Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
[TBL] [Abstract][Full Text] [Related]
12. Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells.
Li C; Qi Q; Lu N; Dai Q; Li F; Wang X; You Q; Guo Q
Biochem Cell Biol; 2012 Dec; 90(6):718-30. PubMed ID: 23194187
[TBL] [Abstract][Full Text] [Related]
13. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
14. Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-line.
Shaik MS; Chatterjee A; Singh M
J Pharm Pharmacol; 2004 Jul; 56(7):899-907. PubMed ID: 15233869
[TBL] [Abstract][Full Text] [Related]
15. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Xu K; Yagüe E
Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation.
Shi R; Peng H; Yuan X; Zhang X; Zhang Y; Fan D; Liu X; Xiong D
J Cell Biochem; 2013 Aug; 114(8):1890-900. PubMed ID: 23494858
[TBL] [Abstract][Full Text] [Related]
17. Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells.
Shi Y; Yu Y; Wang Z; Wang H; Bieerkehazhi S; Zhao Y; Suzuk L; Zhang H
Oncotarget; 2016 Nov; 7(45):73697-73710. PubMed ID: 27655642
[TBL] [Abstract][Full Text] [Related]
18. Schisandrin B reverses doxorubicin resistance through inhibiting P-glycoprotein and promoting proteasome-mediated degradation of survivin.
Wang S; Wang A; Shao M; Lin L; Li P; Wang Y
Sci Rep; 2017 Aug; 7(1):8419. PubMed ID: 28827665
[TBL] [Abstract][Full Text] [Related]
19. [Reversal effect of gambogic acid on multidrug resistance of K562/A02 cell line].
Tian L; Liu J; Chen BA; Cheng J; Ding JH; Wang S; Xia GH; Gao F; Shao ZY; Zhang HJ; Guo QL; Zhang HW; Wang L; Ren YY; Cai XH; Liu R
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Apr; 20(2):252-7. PubMed ID: 22541076
[TBL] [Abstract][Full Text] [Related]
20. VCPA, a novel synthetic derivative of α-tocopheryl succinate, sensitizes human gastric cancer to doxorubicin-induced apoptosis via ROS-dependent mitochondrial dysfunction.
Wu H; Liu S; Gong J; Liu J; Zhang Q; Leng X; Zhang N; Li Y
Cancer Lett; 2017 May; 393():22-32. PubMed ID: 28216375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]